{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:14:54Z","timestamp":1791976494908,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Arcutis Biotherapeutics Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40257-025-00984-2","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:42:05Z","timestamp":1761986525000},"page":"189-198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1351-9165","authenticated-orcid":false,"given":"Andrew F.","family":"Alexis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bukhalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran E.","family":"Cook-Bolden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Q.","family":"Del Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9803-7415","authenticated-orcid":false,"given":"Zoe D.","family":"Draelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7487-7716","authenticated-orcid":false,"given":"Janet C.","family":"DuBois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura K.","family":"Ferris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth B.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Kempers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon H.","family":"Kircik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3805-9441","authenticated-orcid":false,"given":"Edward","family":"Lain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Y.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Pariser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Raoof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8380-8114","authenticated-orcid":false,"given":"Matthew J.","family":"Zirwas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa S.","family":"Seal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Krupa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2103-7185","authenticated-orcid":false,"given":"Patrick","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Berk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"issue":"4","key":"984_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.clindermatol.2013.01.001","volume":"31","author":"C Dessinioti","year":"2013","unstructured":"Dessinioti C, Katsambas A. Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies. Clin Dermatol. 2013;31(4):343\u201351. https:\/\/doi.org\/10.1016\/j.clindermatol.2013.01.001.","journal-title":"Clin Dermatol"},{"issue":"6","key":"984_CR2","first-page":"348","volume":"35","author":"T Berk","year":"2010","unstructured":"Berk T, Scheinfeld N. Seborrheic dermatitis. P T. 2010;35(6):348\u201352.","journal-title":"P T"},{"issue":"5","key":"984_CR3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/exd.14091","volume":"29","author":"JA Adalsteinsson","year":"2020","unstructured":"Adalsteinsson JA, Kaushik S, Muzumdar S, et al. An update on the microbiology, immunology and genetics of seborrheic dermatitis. Exp Dermatol. 2020;29(5):481\u20139. https:\/\/doi.org\/10.1111\/exd.14091.","journal-title":"Exp Dermatol"},{"key":"984_CR4","doi-asserted-by":"publisher","DOI":"10.13188\/2373-1044.1000019","author":"LJ Borda","year":"2015","unstructured":"Borda LJ, Wikramanayake TC. Seborrheic dermatitis and dandruff: a comprehensive review. J Clin Investig Dermatol. 2015. https:\/\/doi.org\/10.13188\/2373-1044.1000019.","journal-title":"J Clin Investig Dermatol."},{"key":"984_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-02830-7","volume":"316","author":"C Chang","year":"2024","unstructured":"Chang C, Chovatiya R. More yeast, more problems?: reevaluating the role of Malassezia in seborrheic dermatitis. Arch Dermatol Res. 2024;316:100. https:\/\/doi.org\/10.1007\/s00403-024-02830-7.","journal-title":"Arch Dermatol Res"},{"key":"984_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.01.082","volume-title":"Tape-strip profiling identifies unique immune and lipid dysregulation in patients with seborrheic dermatitis","author":"B Ungar","year":"2025","unstructured":"Ungar B, Manson M, Kim M, et al. Tape-strip profiling identifies unique immune and lipid dysregulation in patients with seborrheic dermatitis. J Am Acad Dermatol. 2025;92(6):1277\u201387. https:\/\/doi.org\/10.1016\/j.jaad.2025.01.082."},{"key":"984_CR7","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/exd.14006","volume":"28","author":"TC Wikramanayake","year":"2019","unstructured":"Wikramanayake TC, Borda LJ, Miteva M, et al. Seborrheic dermatitis\u2014looking beyond Malassezia. Exp Dermatol. 2019;28:991\u20131001. https:\/\/doi.org\/10.1111\/exd.14006.","journal-title":"Exp Dermatol"},{"key":"984_CR8","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.2147\/CCID.S284671","volume":"15","author":"F Dall'Oglio","year":"2022","unstructured":"Dall\u2019Oglio F, Nasca MR, Gerbino C, et al. An overview of the diagnosis and management of seborrheic dermatitis. Clin Cosmet Investig Dermatol. 2022;15:1537\u201348. https:\/\/doi.org\/10.2147\/CCID.S284671.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"1","key":"984_CR9","first-page":"24","volume":"18","author":"M Elgash","year":"2019","unstructured":"Elgash M, Dlova N, Ogunleye T, et al. Seborrheic dermatitis in skin of color: clinical considerations. J Drugs Dermatol. 2019;18(1):24\u20137.","journal-title":"J Drugs Dermatol"},{"key":"984_CR10","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.intimp.2016.03.025","volume":"35","author":"M Bros","year":"2016","unstructured":"Bros M, Montermann E, Cholaszczy\u0144ska A, et al. The phosphodiesterase 4 inhibitor roflumilast augments the Th17-promoting capability of dendritic cells by enhancing IL-23 production, and impairs their T cell stimulatory activity due to elevated IL-10. Int Immunopharmacol. 2016;35:174\u201384. https:\/\/doi.org\/10.1016\/j.intimp.2016.03.025.","journal-title":"Int Immunopharmacol"},{"key":"984_CR11","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.3390\/cells11101683","volume":"11","author":"P Das","year":"2022","unstructured":"Das P, Mounika P, Yellurkar ML, et al. Keratinocytes: an enigmatic factor in atopic dermatitis. Cells. 2022;11:1683. https:\/\/doi.org\/10.3390\/cells11101683.","journal-title":"Cells"},{"issue":"3","key":"984_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1124\/jpet.116.232819","volume":"358","author":"C Dong","year":"2016","unstructured":"Dong C, Virtucio C, Zemska O, et al. Treatment of skin inflammation with benzoxaborole phosphodiesterase inhibitors: selectivity, cellular activity, and effect on cytokines associated with skin inflammation and skin architecture changes. J Pharmacol Exp Ther. 2016;358(3):413\u201322. https:\/\/doi.org\/10.1124\/jpet.116.232819.","journal-title":"J Pharmacol Exp Ther"},{"key":"984_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/exd.12606","volume":"24","author":"H Wakita","year":"2015","unstructured":"Wakita H, Ohkuro M, Ishii N, et al. A putative antipruritic mechanism of the phosphodiesterase-4 inhibitor E6005 by attenuating capsaicin-induced depolarization of C-fibre nerves. Exp Dermatol. 2015;24:215\u20136. https:\/\/doi.org\/10.1111\/exd.12606.","journal-title":"Exp Dermatol"},{"key":"984_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.865715","volume":"13","author":"R Xu","year":"2022","unstructured":"Xu R, Feng S, Ao Z, et al. Long-acting \u03b22 adrenergic receptor agonist ameliorates imiquimod-induced psoriasis-like skin lesion by regulating keratinocyte proliferation and apoptosis. Front Pharmacol. 2022;13:865715. https:\/\/doi.org\/10.3389\/fphar.2022.865715.","journal-title":"Front Pharmacol"},{"issue":"3 Suppl 1","key":"984_CR15","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.jaad.2017.11.056","volume":"78","author":"R Zebda","year":"2018","unstructured":"Zebda R, Paller AS. Phosphodiesterase 4 inhibitors. J Am Acad Dermatol. 2018;78(3 Suppl 1):S43\u201352. https:\/\/doi.org\/10.1016\/j.jaad.2017.11.056.","journal-title":"J Am Acad Dermatol"},{"key":"984_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.10.597","author":"J Wang","year":"2025","unstructured":"Wang J, Ho M, Bunick CG. Chemical, biochemical, and structural similarities and differences of dermatological cAMP phosphodiesterase-IV inhibitors. J Investig Dermatol. 2025;145(6):1471-88.e1.2024. https:\/\/doi.org\/10.1016\/j.jid.2024.10.597.","journal-title":"J Investig Dermatol"},{"issue":"5","key":"984_CR17","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.jaad.2023.12.065","volume":"90","author":"A Blauvelt","year":"2024","unstructured":"Blauvelt A, Draelos ZD, Stein Gold L, et al. Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: a randomized, double-blinded, vehicle-controlled, phase 3 trial. J Am Acad Dermatol. 2024;90(5):986\u201393. https:\/\/doi.org\/10.1016\/j.jaad.2023.12.065.","journal-title":"J Am Acad Dermatol"},{"key":"984_CR18","first-page":"30","volume":"17","author":"R Chovatiya","year":"2024","unstructured":"Chovatiya R, Polaskey MT, Schlesinger T, et al. Putting the formulation back in foam: optimizing seborrheic dermatitis treatment across diverse hair types. J Clin Aesthet Dermatol. 2024;17:30\u20133.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"4","key":"984_CR19","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/bjd\/ljad182","volume":"189","author":"LH Kircik","year":"2023","unstructured":"Kircik LH, Alonso-Llamazares J, Bhatia N, et al. Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study. Br J Dermatol. 2023;189(4):392\u20139. https:\/\/doi.org\/10.1093\/bjd\/ljad182.","journal-title":"Br J Dermatol"},{"issue":"11","key":"984_CR20","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jama.2022.15632","volume":"328","author":"MG Lebwohl","year":"2022","unstructured":"Lebwohl MG, Kircik LH, Moore AY, et al. Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis: the DERMIS-1 and DERMIS-2 randomized clinical trials. JAMA. 2022;328(11):1073\u201384. https:\/\/doi.org\/10.1001\/jama.2022.15632.","journal-title":"JAMA"},{"issue":"2","key":"984_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.36849\/jdd.7295","volume":"22","author":"M Gooderham","year":"2023","unstructured":"Gooderham M, Kircik L, Zirwas M, et al. The safety and efficacy of roflumilast cream 0.15% and 0.05% in patients with atopic dermatitis: randomized, double-blind, phase 2 proof of concept study. J Drugs Dermatol. 2023;22(2):139\u201347. https:\/\/doi.org\/10.36849\/jdd.7295.","journal-title":"J Drugs Dermatol"},{"key":"984_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.3121","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Eichenfield LF, Alonso-Llamazares J, et al. Roflumilast cream, 0.15%, for improving atopic dermatitis in adults and children: INTEGUMENT-1 and INTEGUMENT-2 randomized clinical trials. JAMA Dermatol. 2024. https:\/\/doi.org\/10.1001\/jamadermatol.2024.3121.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"984_CR23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1001\/jamadermatol.2023.0846","volume":"159","author":"MJ Zirwas","year":"2023","unstructured":"Zirwas MJ, Draelos ZD, DuBois J, et al. Efficacy of roflumilast foam, 0.3%, in patients with seborrheic dermatitis: a double-blind, vehicle-controlled phase 2a randomized clinical trial. JAMA Dermatol. 2023;159(6):613\u201320. https:\/\/doi.org\/10.1001\/jamadermatol.2023.0846.","journal-title":"JAMA Dermatol"},{"key":"984_CR24","doi-asserted-by":"publisher","unstructured":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134. https:\/\/doi.org\/10.1001\/jama.2013.281053.","DOI":"10.1001\/jama.2013.281053"},{"key":"984_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/105294199277860","volume":"6","author":"JRJ Dixon","year":"1998","unstructured":"Dixon JRJ. The international conference on harmonization good clinical practice guideline. Qual Assur. 1998;6:65\u201374. https:\/\/doi.org\/10.1080\/105294199277860.","journal-title":"Qual Assur"},{"issue":"6","key":"984_CR26","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/ijd.12645","volume":"54","author":"AN Naegeli","year":"2015","unstructured":"Naegeli AN, Flood E, Tucker J, et al. The worst itch numeric rating scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis. Int J Dermatol. 2015;54(6):715\u201322. https:\/\/doi.org\/10.1111\/ijd.12645.","journal-title":"Int J Dermatol"},{"issue":"6","key":"984_CR27","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1001\/archderm.138.6.803","volume":"138","author":"SC Chen","year":"2002","unstructured":"Chen SC, Yeung J, Chren M-M. Scalpdex: a quality-of-life instrument for scalp dermatitis. Arch Dermatol. 2002;138(6):803\u20137. https:\/\/doi.org\/10.1001\/archderm.138.6.803.","journal-title":"Arch Dermatol"},{"key":"984_CR28","unstructured":"OTEZLA (apremilast) tablets. Prescribing information. Thousand Oaks, CA: Amgen Inc.; 2024."},{"key":"984_CR29","unstructured":"DALIRESP (roflumilast) tablets. Prescribing information. Wilmington, DE: AstraZeneca Pharmaceuticals, LP; 2020."},{"key":"984_CR30","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s13555-024-01161-9","volume":"14","author":"MT Polaskey","year":"2024","unstructured":"Polaskey MT, Woolery-Llloyd H, Osborne D, et al. When patient diversity informs formulation: reimagining treatment for seborrheic dermatitis. Dermatol Ther (Heidelb). 2024;14:1071\u20137. https:\/\/doi.org\/10.1007\/s13555-024-01161-9.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"984_CR31","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1111\/jdv.19913","volume":"38","author":"C Zeidler","year":"2024","unstructured":"Zeidler C, Kupfer J, Dalgard FJ, et al. Dermatological patients with itch report more stress, stigmatization experience, anxiety and depression compared to patients without itch: results from a European multi-centre study. J Eur Acad Dermatol Venereol. 2024;38:1649\u201361. https:\/\/doi.org\/10.1111\/jdv.19913.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"984_CR32","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1001\/archdermatol.2011.178","volume":"147","author":"SP Kini","year":"2011","unstructured":"Kini SP, DeLong LK, Veledar E, et al. The impact of pruritus on quality of life: the skin equivalent of pain. Arch Dermatol. 2011;147(10):1153\u20136. https:\/\/doi.org\/10.1001\/archdermatol.2011.178.","journal-title":"Arch Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00984-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00984-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00984-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:50:56Z","timestamp":1769849456000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00984-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["984"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00984-2","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrew F. Alexis received grants (funds to institution) from AbbVie, Amgen, Arcutis, Castle Biosciences, Dermavant, Galderma, Incyte, and LEO Pharma; served on advisory boards or as a consultant for AbbVie, Allergan, Almirall, Alphyn Biologics, Amgen, Apogee Therapeutics, Arcutis, AVITA Medical, Bausch Health, Beiersdorf, BMS, Boehringer Ingelheim, Canfield Scientific, Cara Therapeutics, Castle Biosciences, Cutera, Dermavant, EPI Health, Galderma, Genentech, Genzyme, Incyte, LEO Pharma, Lilly, L\u2019Oreal, Janssen, Ortho Dermatologics, Pfizer, Sanofi Regeneron, Swiss American, UCB, and VisualDx; is a speaker for Aerolase, BMS, Janssen, Johnson & Johnson, L\u2019Oreal, Regeneron, and Sanofi Genzyme; receives royalties from Elsevier, Wiley-Blackwell, and Wolters Kluwer Health; and received equipment from Aerolase. Michael Bukhalo is an investigator for Arcutis and received grants\/research funding and honoraria. Fran E. Cook-Bolden serves as an advisory board member for AbbVie, Dermavant, Galderma, Novartis, Ortho Dermatologics, and Pfizer; as an investigator for Arcutis; as a speaker for Galderma, Journey Medical Corporation, and Ortho Dermatologics; and has received other financial benefit from Topix Pharmaceuticals. James Q. Del Rosso received investigator fees, speaker fees, clinical research grants, and\/or honoraria from Aclaris, Almirall, Amgen, AnaptysBio, Arcutis, Ath\u0113nix, Biofrontera, BioPharmX, Biorasi, BlueCreek Dermatologics, BMS, Botanix, Brickell Biotech, Cara Therapeutics, Cassiopea SpA, Dermata, Dermavant, Dermira, Encore Dermatology, Evommune, Ferndale Laboratories, Foamix, Galderma, Genentech, Incyte, JEM Health, L\u2019Oreal, La Roche-Posay, LEO Pharma, Lilly, Mayne Pharma, Menlo Therapeutics, Novan, Ortho Dermatologics, Pfizer, Promius Pharma, Ralexar, Regeneron, Sanofi Genzyme, Sebacia, Sent\u00e9, Sol-Gel Technologies, Sonoma Pharmaceuticals, Sun Pharma, Trevi Therapeutics, UCB, Unilever Home & Personal Care, Verrica, and Viamet; and received salary as an employee of Regeneron. Zoe D. Draelos received a research grant from Arcutis to contribute to the study presented in the paper. Janet C. DuBois is an investigator for and receives grants\/research funding from AbbVie, Accure for Acne, Acrotech Biopharma, Amplifica, Arcutis, Biofrontera, Bluefin Biomedicine, BMS, Brickell Biotech, Caliway Biopharmaceuticals, Cara Therapeutics, Cassiopea SpA, Croma-Pharma, Dermata, DermBiont, Incyte, Medytox, Merck, Moberg Pharma, Nail Genesis, Nielsen Biosciences, Q32 Bio, RAPT Therapeutics, Sanofi, Scarless Laboratories, TechnoDerma, Therapeutics Inc., and VeraDermics. Laura K. Ferris received consulting fees, investigator fees, speaker fees, clinical research grants, sponsored research, and\/or honoraria from AbbVie, Amgen, Boehringer Ingelheim, BMS, Dermavant, Janssen, Lilly, Nimbus Therapeutics, Novartis, and UCB. Seth B. Forman is an investigator for Arcutis and received grants\/research funding and honoraria. Steven E. Kempers is an investigator for Arcutis and received grants\/research funding and honoraria. Leon H. Kircik received investigator fees, speaker fees, clinical research grants, and\/or honoraria from 3M Pharmaceuticals, Abbott, Ablynx, Acambis, Allergan, Almirall, Amgen, AnaptysBio, Aqua Pharmaceuticals, Arcutis, Astellas, Asubio, Bayer Consumer Health, Beiersdorf, Biogen, Biolife, Biopelle, BMS, Boehringer Ingelheim, Botanix, Breckinridge Pharma, Cassiopea SpA, Celgene, Cellceutix, Centocor, ChemoCentryx, ColBar LifeScience, CollaGenex Pharmaceuticals, Connetics Corporation, Coria Laboratories, Dermavant, Dermik (a business of Sanofi Aventis), Dow Pharmaceutical Sciences, DUSA Pharmaceuticals, Embil Pharmaceutical Co, EOS Pharmaceutical Corp, Ferndale Laboratories, Galderma, Genentech, GSK, Healthpoint, Incyte, Intendis, ISDIN, Johnson & Johnson Consumer Products, Laboratory Skin Care, LEO Pharma, MC2 Therapeutics, Medical International Technologies, Medicis, Merck, Merck Serono, Merz Pharmaceuticals, NanoBio Corporation, Novartis, Nucryst, Obagi Medical, Onset Dermatologics, Ortho Dermatologics, Pfizer, Pharmaderm, Promius Pharma, PuraCap, QLT Inc., Sandoz (a Novartis company), SkinMedica, Stiefel (a GSK company), Sun Pharma, Taro Pharmaceuticals, TolerRx, Triax Pharmaceuticals, Valeant, Warner Chilcott, Xenoport, and Zalicus. Edward Lain is an investigator for Arcutis and received grants\/research funding and honoraria. Angela Y. Moore received research funds or honoraria from AbbVie, Almirall, Arcutis, BMS, Cara Therapeutics, Dermavant, Galderma, Janssen, Incyte, Lilly, Novartis, Pfizer, Sanofi, Takeda, UCB, and Vyne. David M. Pariser is an investigator for and receives grants\/research funding and\/or honoraria from Almirall, Amgen, AOBiome, Asana BioSciences, Brickell Biotech, Celgene, Dermira, LEO Pharma, Lilly, Menlo Therapeutics, Novartis, Novo Nordisk, Ortho Dermatologics, Pfizer, and Regeneron; is a consultant and\/or serves on an advisory board for and receives honoraria from Biofrontera, Brickell Biotech, Dermira, Novartis, Pfizer, Regeneron, and Sanofi; and is on the data safety monitoring board and receives honoraria from BMS. Joseph Raoof has served as an investigator for AbbVie, Arcutis, AstraZeneca, Bausch Health, BMS, Boehringer Ingelheim, Dermavant, Dermira, Galderma, GSK, Incyte, Janssen, LEO Pharma, Lilly, Pfizer, Regeneron, Sanofi Genzyme, and UCB. Matthew J. Zirwas received consulting fees, investigator fees, speaker fees, clinical research grants, and\/or honoraria from and\/or has participated in sponsored research for AbbVie, All Free Clear\/Sun, AnaptysBio, Arcutis, Asana Biosciences, Aseptic MD, Avillion, Bausch Health, Cara Therapeutics, Concert Pharmaceuticals, Dermavant, Edesa, EPI Health, Fitbit, Galderma, Genentech\/Novartis, Incyte, Janssen, L\u2019Oreal, LEO Pharma, Level Ex, Lilly, LUUM, Oculus, Peloton, Pfizer, Sanofi Regeneron, Sol-Gel Technologies, Trevi Therapeutics, UCB, and Vyne. Melissa S. Seal, Saori Kato, David H. Chu, David Krupa, Scott Snyder, Patrick Burnett, and David R. Berk are employees of Arcutis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data collected for this study will be made available to others. Proposals for data requests will be reviewed and considered for sharing following approval of the indication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The protocol was approved by the WCG Institutional Review Board (IRB Tracking Number: 20201067), and local institutional review boards for sites not covered by this central institutional review board. The trial was conducted in accordance with the principles of the 1964 Declaration of Helsinki and its later amendments, with the exception that this trial was retrospectively registered. The trial was posted to clinicaltrials.gov no later than 21 days after enrollment of the first participant in accordance with the Food and Drug Administration Amendments Act (FDAAA) 801 guidance.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients at screening prior to trial enrollment; assent was also obtained when applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent on file: consent to participate"}},{"value":"The investigators obtained written consent from patients for their photographs and medical information to be published in print and online with the understanding that this information may be publicly available. Patient consent forms were not provided to the journal but were retained by the investigators.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Andrew F. Alexis had full access to all data in the trial and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Seal, Kato, Chu, Krupa, Snyder, Burnett, and Berk. Acquisition, analysis, or interpretation of data: all authors. Drafting of the manuscript: all authors. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: Krupa. Supervision: Seal, Kato, Chu, Krupa, Snyder, Burnett, and Berk. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}